Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

被引：0
作者：
Shinichi Komiyama
Kazuyoshi Kato
Yuki Inokuchi
Hirokuni Takano
Takashi Matsumoto
Atsushi Hongo
Mikiko Asai-Sato
Atsushi Arakawa
Shoji Kamiura
Tsutomu Tabata
Nobuhiro Takeshima
Toru Sugiyama
机构：
[1] Toho University Ohashi Medical Center,Department of Gynecology
[2] Cancer Institute Hospital,Department of Gynecology
[3] Kitasato University,Department of Biostatistics, Kitasato Academic Research Organization
[4] The Jikei University Kashiwa Hospital,Department of Obstetrics and Gynecology
[5] Ehime University School of Medicine,Department of Obstetrics and Gynecology
[6] Kawasaki Medical School,Department of Obstetrics and Gynecology 2
[7] Yokohama City University School of Medicine,Department of Obstetrics and Gynecology
[8] Nagoya City University Graduate School of Medical Sciences,Department of Obstetrics and Gynecology
[9] Osaka International Cancer Institute,Department of Gynecologic Oncology
[10] Mie University Faculty of Medicine,Department of Obstetrics and Gynecology
[11] Iwate Medical University,Department of Obstetrics and Gynecology
来源：
International Journal of Clinical Oncology | 2019年 / 24卷
关键词：
Advanced epithelial ovarian cancer; First-line chemotherapy; Bevacizumab; Paclitaxel plus carboplatin; Platinum-free interval;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：103 / 114
页数：11
相关论文
共 64 条
  • [1] Matulonis UA(2016)Ovarian cancer Nat Rev Dis Primers 2 16061-2483
  • [2] Sood AK(2011)Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2473-2496
  • [3] Fallowfield L(2011)A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2484-367
  • [4] Burger RA(2012)Randomized phase II study of first-line carboplatin–paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer Lung Cancer 76 362-2556
  • [5] Brady MF(2006)Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 24 2549-3382
  • [6] Bookman MA(2014)Incorporation of pazopanib in maintenance therapy of ovarian cancer J Clin Oncol 32 3374-247
  • [7] Perren TJ(2015)Specific safety profile of bevacizumab in Asian patients with advanced NSCLC: a meta-analysis Medicine (Baltimore) 94 e975-58
  • [8] Swart AM(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-1217
  • [9] Pfisterer J(2017)Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA Single-Arm Phase 3B Study Int J Gynecol Cancer 27 50-748
  • [10] Niho S(2014)Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 32 1210-2589
1234567